Follow-up of a Patient with Primary Vitreoretinal Lymphoma up to 5 Years

Background: Primary Vitreoretinal Lymphoma (PVRL) is a rare ocular malignant tumor, belonging to a special subtype of primary central nervous system lymphoma (PCNSL). In the early stage of PVRL, the main manifestations are blurred vision, decreased vision and floating objects in front of the eyes. It is prone to invade the central nervous system and has a poor prognosis. As PVRL is extremely rare, much information about this disease is not fully understood at present and there is no standard treatment plan. So far, there are few relevant literatures on the long-term follow-up of PVRL. Case Introduction: On March 17, 2020, a 68-year-old female patient who was admitted to the hospital with uveitis in both eyes was diagnosed with camouflage syndrome caused by intraocular lymphoma in both eyes after comprehensive examination and differentiation. After the initial treatment at Hebei Eye Hospital, the patient was followed up and observed. From March 2020 to September 2025, the patient regularly underwent ocular re-examinations and intravitreal injection + anterior chamber puncture at Hebei Eye Hospital. At the same time, the patient received regular systemic chemotherapy. The patient's ocular condition was stable. Conclusion: VRL is a malignant tumor with a high risk of recurrence and metastasis. It requires long-term and close follow-up, as well as the integration of systemic treatment and local ocular intervention. For patients diagnosed with VRL, even if there is already systemic metastasis, through an integrated strategy of intravitreal injection combined with systemic treatment and maintaining long-term and stable treatment, it is still possible to maintain stable vision during a follow-up period of up to 5 years. The results of this study confirm that continuous comprehensive treatment is the key to preserving patients' visual function.